Work

Surgery of IDH-mutated grade 2 glioma: continually setting the bar higher

Year: 2024

Type: article

Abstract: Over the last twenty years, major advances have been achieved in the management of patients diagnosed with an isocitrate dehydrogenase (IDH)-mutated grade 2 glioma. Two randomized trials provided important data. First, long-term survival was demonstrated to be significantly improved (13.3 versus 7.8 years) by adding chemotherapy (procarbazine—CCNU–vincristine) to radiation therapy.1 Second, the short-term progression free survival was found to be much longer in the arm treated by vorasidenib (a new well-tolerated drug targeting IDH-mutation) rather than placebo.

Source: The Lancet Regional Health - Europe

DOI: 10.1016/j.lanepe.2024.101099

Author: Emmanuel Mandonnet

Institutions: Centre National de la Recherche Scientifique, Inserm, Université Paris Cité, Hôpital Lariboisière, Institut du Cerveau

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,000